Strategic partnerships GlycoSeLect has a history of distributing partnerships and collaborations with industry players (BioLynx, DBA Italia, Osbindia) and a platform-involved collaboration with Allergan and others. This suggests a sales opportunity to leverage or expand channel partnerships and distributor networks in new regions or segments, emphasizing rapid access to GlycoSeLect’s RPLs for clinical and industrial customers.

Market expansion Recent alliance activity across Europe and Asia indicates appetite for geographic expansion and multi-market supply. Target opportunities include life sciences labs, biopharma manufacturers, and contract research organizations that need scalable, high-purity glycan-binding reagents for glycoproteomics, vaccines, and biotherapeutic quality control.

Product differentiation RPLs offer simplified production in E. coli with high purity and scalable manufacturing, plus improved specificity and affinity. This creates selling points to win customers seeking cost-effective, reliable alternatives to traditional lectins for glycan analysis, purification, and diagnostics across biotech and pharma pipelines.

Niche focus With a small team and revenue under one million, GlycoSeLect presents a high-touch, specialized sales approach. Opportunities exist to upsell research institutes and niche biotechs requiring advanced glycoscience tools, leveraging tailored demonstrations, pilots, and contractual RPL access.

Funding and momentum Evidence of fundraising interest and ongoing collaborations signals buyer and investor confidence. A targeted outreach to potential funders or co-development partners could unlock joint development projects, licensing deals, or strategic sales of RPL-based ligands to large manufacturers seeking glycan-specific solutions.